Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : WHO awaits AstraZeneca data, says more vaccines needed

11/23/2020 | 01:42pm EST

GENEVA (Reuters) - The World Health Organization's chief scientist said on Monday the organisation was waiting to see the efficacy and safety of AstraZeneca's COVID-19 vaccine and urged other developers to maintain efforts in order to provide enough doses for billions of people.

AstraZeneca said on Monday its COVID-19 vaccine could be around 90% effective, giving the world's fight against the global pandemic a new weapon - cheaper to make, easier to distribute and faster to scale-up than rivals.

The WHO's chief scientist, Soumya Swaminathan, said that the company's highest reported success rates of around 90 percent was "encouraging" but based on "rather small numbers."

"I think we need to wait to see the results for both the efficacy and the safety," she added, saying the firm was nevertheless in talks for it to be included in the WHO's pre-qualification list which serves as a procurement benchmark.

Swaminathan urged other developers to continue work, saying a variety of vaccines would be required to meet global needs.

"Remember we have to cover a huge number of people, billions of billions of people, and this is unprecedented. We will need all the manufacturing capacity in the world in order to do that," she said.

She also said she hoped other "heat stable" vaccines like AstraZeneca's, which can be stored in a refrigerator, would emerge.

(Reporting by Stephanie Nebehay and Emma Farge in Geneva and Michael Shields in Zurich; Editing by Alex Richardson and Cynthia Osterman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
MODERNA, INC. -1.47% 131.02 Delayed Quote.25.41%
All news about ASTRAZENECA PLC
03:26pTHE LATEST : Chicago opens restaurants, some bars with limits
AQ
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
RE
12:49pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
DJ
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
AQ
11:38aItaly PM says vaccine supply delays are serious contract violations
RE
06:06aTHE LATEST : N.Y. seniors, churches to get vaccine prep kits
AQ
03:45aASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
RE
01/22Health Care Down Amid Vaccine-Rollout Concerns -- Health Care Roundup
DJ
01/22THE LATEST : Online vaccine appointments filling up in Kansas
AQ
01/22ALEXION INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159